Skip to content

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Plaque Psoriasis In The Italian Setting

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Plaque Psoriasis In The Italian Setting 1

COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING Author(s) Barbieri M1, Capri S2, Oskar B31Centre for Health Economics, University of York, York, UK, 2School of Economics and Management Cattaneo – LIUC University, Castellanza, Italy, 3Celgene Corporation, Milan, Italy View presentation Content OBJECTIVES: This analysis assessed the value of apremilast in adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapy in the Italian setting. Treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultraviolet A. Apremilast has not yet been addressed in published guidelines. A cost-utility analysis of psoriasis treatment in Italy has shown that etanercept treatment is a cost-effective therapy from the health service perspective and that the cost-effectiveness of etanercept increases with disease severity (incremental cost-effectiveness ratios for moderate-to-severe and severe psoriasis: 33,216 and 25,486 per QoL year, respectively) 78. Biologicals have changed psoriasis treatment standards, not only effectiveness, but in allowing the management of patients in an out-patient setting. Cost-Effectiveness Analysis of Conbercept Versus Ranibizumab For The Treatment of Age-Related Macular Degeneration In China. Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain.

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Plaque Psoriasis In The Italian Setting 2Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis In The Italian Setting. Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain. Value Health. Value Health 2015 Nov 20;18(7):A645. Epub 2015 Oct 20. Same-Day Analysis Australia’s PBAC recommends 17 listings including Gilead’s Harvoni and Sovaldi. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered; and. The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor. Menarini (Italy). Moderate-to-severe plaque psoriasis. Health and the PBAC to make Apremilast available for Australian patients.

FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands. The 2009 European evidence-based S3-guidelines on psoriasis treatment recommend FAE and suggest it as a first-line systemic treatment for moderate-to-severe plaque psoriasis. Using this treatment regimen, Sch fer reported good effectiveness results in treating psoriasis patients with FAE on a large scale in a specialized clinic in Leysin, Switzerland. A meta-analysis of the efficacy results of the six RCTs is not feasible due to heterogeneity in efficacy outcomes and incomplete reporting, as some of the earlier RCTs often did not adhere to the current CONSORT guidelines of reporting RCT data. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2). Cost per treated patient for etanercept and ustekinumab in patients treated for moderate to severe plaque psoriasis. Cost-effectiveness of maintenance treatment for 1 year with biologic drugs for moderate to severe psoriasis in the dermatology department of a university hospital. GC-TOF MS analysis reveals metabolite differences in psoriasis and psoriatic arthritis patients compared to healthy individuals. 4/2015Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate QALYs. 6/2014The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. 1/2009A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.

Papers With The Keyword Apremilast (page 2)

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Plaque Psoriasis In The Italian Setting 3

Fumaric Acid Esters In The Management Of Psoriasis